Why Mannkind is Breaking Out

Mannkind MNKD is up today after reports that Afrezza is available at some pharmacies. Photos of the product and packaging were posted online from a Los Angeles pharmacy. It is being reported that the set costs $278 without insurance.

 

 

Mannkind's partner in the launch is Sanofi SNY.

 

Mannkind stock is also breaking out of resistance levels formed over the last three months. The stock had been in a downward trend ever since receiving approval in the middle of last year. Today, the stock is holding above its 50 and 200-day moving averages and the MACD turned positive.

 

Posted In: NewsFDA
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...